Diabetes’ JDRF Tries Shock Ad to Push the FDA
This is not a story about statistics, yet I have to start there. It is not a story about a shocking ad that ran in the New York Times and Washington Post, yet the uproar started there.
This is the story of how approximately 150,000 people with type 1 diabetes will die, and one among them, a vibrant, healthy and lovely 17-year-old girl who did die, due to a side effect of insulin.
Insulin, which many think is a cure for type 1 diabetes, is not a cure but a medicine that lowers blood sugar. Sometimes so much, that you die. Did you know that?
This ad ran on Nov. 2 and touched off seismic aftershocks among diabetes bloggers and online advocates.
Most who read the ad were stunned. Parents who have a child with diabetes were terrified or angered. The emotional-hit prompted many to question such an unbelievable figure: 1 in 20 people (an estimated 2-4 percent and 6 percent in patients younger than 40 years old) will perish from severe hypoglycemia.
Of the estimated 3 million people in the U.S. with type 1 diabetes, that’s approximately 150,000 people. That’s like wiping out Chattanooga, Tenn. or Rockford, Ill. — wiping them right off the map.
Aaron Kowalski, Juvenile Diabetes Research Foundation (JDRF) vice president, who’s been in charge of hypoglycemia research funding and helped launch, and still oversees, the Artificial Pancreas Project immediately responded to the uproar online.
He said JDRF ran the ad because they want the FDA to understand that tools and technologies, such as artificial pancreas technologies, exist to minimize dangerous low blood sugar; that researc Continue reading